<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03414255</url>
  </required_header>
  <id_info>
    <org_study_id>AIAT001</org_study_id>
    <nct_id>NCT03414255</nct_id>
  </id_info>
  <brief_title>Micronized dHACM Injectable for the Treatment of Achille Tendonitis</brief_title>
  <official_title>A Phase 3, Prospective, Double-Blinded, Randomized Controlled Trial Of The Micronized dHACM Injection As Compared To Saline Placebo Injection In The Treatment Of Achilles Tendonitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MiMedx Group, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MiMedx Group, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, Double-Blinded, Randomized Controlled Trial of the Micronized dHACM Injection as
      Compared to Saline Placebo Injection in the Treatment of Achilles Tendonitis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 158 subjects will be enrolled in this study. Each patient will receive 1
      injection and be evaluated for efficacy and safety during a 12 month observation period.
      Randomization will be 1:1. The study is expected to be completed in 24 months, inclusive of
      enrollment and follow-up of all subjects.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 9, 2018</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in VAS score</measure>
    <time_frame>90 days</time_frame>
    <description>Visual Analog Scale, Left end point is &quot;No Pain&quot;. Right end point is &quot;worst pain imaginable&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>365 days</time_frame>
    <description>The incidence of related Adverse Events (AEs), Serious Adverse Events (SAEs), and Unanticipated Adverse Events during the first 12 months post injection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Foot Function Index Revised (FFI-R) (Short Form)</measure>
    <time_frame>90 days</time_frame>
    <description>Subjects circle the number that correlates how bad their foot pain was in certain situation.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">158</enrollment>
  <condition>Tendonitis;Achilles</condition>
  <arm_group>
    <arm_group_label>Micronized DHACM</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1mL injection of 40mg Micronized dehydrated human amnion/chorion membrane (DHACM)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Saline Injection</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Injection of 1mL 0.9% Sodium Chloride Injection, USP</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Micronized DHACM</intervention_name>
    <description>1 mL injection of 40mg Micronized dehydrated human amnion/chorion membrane (DHACM).</description>
    <arm_group_label>Micronized DHACM</arm_group_label>
    <other_name>dHACM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saline Injection</intervention_name>
    <description>Injection of 1mL 0.9% Sodium Chloride Injection, USP</description>
    <arm_group_label>Saline Injection</arm_group_label>
    <other_name>0.9% NaCL</other_name>
    <other_name>Normal Saline</other_name>
    <other_name>Sodium Chloride Injection, USP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

        All subjects enrolled must meet all the following criteria:

          1. Confirmed diagnosis of Achilles tendonitis for ≥ 1 month (30 days) and ≤ 18 months by
             the investigator

          2. VAS Pain scale of ≥ 45 at randomization

          3. Achilles Tendonitis with conservative treatment for ≥1 month (30 days) while under the
             direction of the healthcare provider, including any of the following modalities:

               -  Rest, Ice, Compression, Elevation (RICE)

               -  Stretching exercises

               -  Nonsteroidal Anti-inflammatory Drugs (NSAIDs)

               -  Orthotics

          4. Diagnostic AP and lateral X-Ray within 6 months of enrollment showing view of
             calcaneus negative for calcaneal fracture or structural abnormalities

          5. BMI ≤ 40 kg/m2

          6. Age from 21 to 80 years

          7. Ability to sign Informed Consent and Release of Medical Information Forms

          8. Ability to receive and respond to text messages or emails on a daily basis.

        Exclusion Criteria Any potential subjects meeting any of the following criteria will be
        excluded from enrollment and subsequent randomization.

          1. Prior surgery to the affected site.

          2. Subjects requiring bilateral Achilles tendonitis treatment at time of enrollment

          3. Prior use of any lower limb injection therapy, including corticosteroids or PRP in
             either limb within the last 3 months

          4. Has diabetes either Type I or Type II

          5. Systemic disorders associated with enthesopathy (disorder of entheses, i.e. bone
             attachments) such as Gout, Reiter's syndrome, rheumatoid arthritis, etc.

          6. The presence of diagnosed comorbidities that can be confused with or can exacerbate
             the condition- to be assessed by X-ray - including but not limited to:

               -  Calcaneal stress fracture

               -  Suspected partial thickness tear of the Achilles tendon, as assessed by the
                  investigator

               -  Calcaneal tumor

               -  Tarsal tunnel syndrome (diagnosed)

               -  Significant bone deformity of the foot that may interfere with the study

          7. The presence of diagnosed comorbidities that require surgery or are unlikely to
             improve - to be assessed by Investigator-including but not limited to:

               -  Nerve entrapment syndrome

               -  Acute traumatic rupture of the Achilles tendon

               -  Partial thickness tears of the Achilles Tendon

          8. Affected site exhibits clinical signs and symptoms of infection

          9. Known allergy or known sensitivity to Aminoglycosides

         10. Subjects who are non-ambulatory

         11. History of more than 14 days of treatment with immune-suppressants (including systemic
             corticosteroids) or cytotoxic chemotherapy within 30 days prior to enrollment, or who
             are anticipated to require such medications during the course of the study

         12. Prior radiation at the site

         13. Use of any investigational drug(s) or therapeutic device(s) within 3 months preceding
             enrollment

         14. Immune system disorders including Systemic Lupus Erythematosus (SLE), Fibromyalgia,
             Acquired Immunodeficiency Syndrome (AIDS), Human Immunodeficiency Virus (HIV) or Lyme
             disease

         15. History of any conditions (including drug or alcohol abuse, medical or psychiatric
             condition) that is likely to impair understanding of or compliance with the study
             protocol, in the judgment of the investigator

         16. Pregnancy at enrollment or within last 6 months, women who are breastfeeding, or women
             of childbearing potential who are planning to become pregnant during the time of the
             study OR are unwilling/unable to use acceptable methods of contraception (birth
             control pills, barriers, or abstinence)

         17. Workers' compensation patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stuart D Miller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MedStar Union Memorial Hospital Baltimore, MD</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stanley J Harris</last_name>
    <phone>770-651-9100</phone>
    <email>sharris@mimedx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Don Fetterolf, MD</last_name>
    <phone>770-651-9100</phone>
    <email>dfetterolf@mimedx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Central Research Associates</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shellie Talley, LPN</last_name>
    </contact>
    <investigator>
      <last_name>Jeffrey Davis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Limb Preservation Platform, Inc</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93721</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Destiny Stegall</last_name>
      <phone>559-431-1700</phone>
    </contact>
    <investigator>
      <last_name>Shawn Cazzell, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northside Podiatry</name>
      <address>
        <city>Buford</city>
        <state>Georgia</state>
        <zip>30518</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay Spector, DPM</last_name>
    </contact>
    <investigator>
      <last_name>Jay Spector, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Foot and Ankle Center of Illinois</name>
      <address>
        <city>Springfield</city>
        <state>Illinois</state>
        <zip>62704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlene Pappas, RN</last_name>
    </contact>
    <investigator>
      <last_name>John Sigle, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Orthopedics Center</name>
      <address>
        <city>Altoona</city>
        <state>Pennsylvania</state>
        <zip>16602</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martina Snyder</last_name>
    </contact>
    <investigator>
      <last_name>Alexis Ley, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Orthopedics Center</name>
      <address>
        <city>State College</city>
        <state>Pennsylvania</state>
        <zip>16801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sue Jepson, RN</last_name>
    </contact>
    <investigator>
      <last_name>Bradley Barter, DO</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Coastal Podiatry, Inc.</name>
      <address>
        <city>Virginia Beach</city>
        <state>Virginia</state>
        <zip>23464</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen McGee</last_name>
      <phone>757-523-0414</phone>
    </contact>
    <investigator>
      <last_name>Patrick S Agnew, DPM</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2018</study_first_submitted>
  <study_first_submitted_qc>January 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2018</study_first_posted>
  <last_update_submitted>January 29, 2018</last_update_submitted>
  <last_update_submitted_qc>January 29, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic Achilles Tendonitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tendinopathy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

